Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.

Studies were performed to elucidate the mechanism of alum gel coagulation upon freezing and drying and its relationship to vaccine potency loss and to develop a novel freeze-drying process for the production of stable alum-adjuvanted vaccine formulations suitable for conventional needle injection and epidermal powder immunization (EPI). The alum hydroxide-adjuvanted hepatitis-B surface antigen (Alum-HBsAg) and the alum phosphate-adjuvanted diphtheria and tetanus toxoids (Alum-DT) were dehydrated by freeze drying (FD), spray drying (SD), air drying (AD), or spray freeze drying (SFD). After drying by FD, SD, or AD, alum gels coagulated when examined by optical microscopy and particle size analysis. In addition, desorption of antigen molecules from the coagulated when examined by optical microscopy and particle size analysis. In addition, desorption of antigen molecules from the coagulated alum gel upon reconstitution appeared to be difficult, as indicated by attenuated band intensity on SDS-PAGE. In contrast, SFD alum gels turned a homogenous suspension upon reconstitution, suggesting minimal alum coagulation. In the mouse model, the in vivo immunogenicity of SFD Alum-HBsAg was preserved, whereas the FD Alum-HBsAg suffered significant immunogenicity loss. Grinding of coagulated FD Alum-HBsAg into smaller particles could partially recover the immunogenicity. In a guinea pig study using EPI, the SD Alum-DT formulation was not immunogenic, but the SFD Alum-DT formulations had a vaccine potency comparable to that of the untreated DT administered by I.M. injection. Overall, the relationship of coagulation of alum gel upon reconstitution and the loss of vaccine potency was established in this study. Alum gels became highly coagulated after dehydration by spray drying and traditional freeze-drying processes. However, freezing rate played a critical role in preserving the adjuvant effect of alum and fast freezing decreased the tendency of alum coagulation. Spraying the alum gel into liquid nitrogen represents the fastest freezing rate achievable and resulted in no discernible alum coagulation. Therefore, SFD presents a novel and effective drying process for alum-adjuvanted vaccine formulations and is particularly valuable for dry powder applications such as EPI.

[1]  Y. Barenholz,et al.  Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. , 1999, Vaccine.

[2]  S. Flohe,et al.  Antigen‐pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major , 1998, European journal of immunology.

[3]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[4]  A. Shafferman,et al.  Novel Adjuvant Strategies for Experimental Malaria and AIDS Vaccines , 1993, Annals of the New York Academy of Sciences.

[5]  S J Prestrelski,et al.  Biopharmaceutical powders: particle formation and formulation considerations. , 2000, Current pharmaceutical biotechnology.

[6]  V. B. Joshi,et al.  Field trial on frozen and thawed tetanus toxoid. , 1976, The Indian journal of medical research.

[7]  Simon C Watkins,et al.  DNA–based immunization by in vivo transfection of dendritic cells , 1996, Nature Medicine.

[8]  J. White,et al.  Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. , 1984, Journal of pharmaceutical sciences.

[9]  A. M. Polillio,et al.  Does a needleless injection system reduce anxiety in children receiving intramuscular injections? , 1997, Pediatric nursing.

[10]  L. Chedid,et al.  Current status of immunological adjuvants. , 1986, Annual review of immunology.

[11]  A. Adamson Physical chemistry of surfaces , 1960 .

[12]  J. Clements,et al.  Bacterial toxins as mucosal adjuvants. , 1999, Current topics in microbiology and immunology.

[13]  W. Shalaby Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. , 1995, Clinical immunology and immunopathology.

[14]  Y. Maa,et al.  Adjuvantation of epidermal powder immunization. , 2001, Vaccine.

[15]  R. Gupta,et al.  Adjuvant properties of aluminum and calcium compounds. , 1995, Pharmaceutical biotechnology.

[16]  Steven J. Shire,et al.  Protein Inhalation Powders: Spray Drying vs Spray Freeze Drying , 1999, Pharmaceutical Research.